Radioligand fOr locAl raDiorecurrent proStaTe cancER
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Approximately 50-60% of men undergoing salvage brachytherapy post cancer recurrence to the
prostate have the disease controlled at 5 years. This study aims to integrate a local
treatment to the prostate (brachytherapy) with a treatment involving 177Lutetium (Lu)-
Prostate-Specific Membrane Antigen (PSMA) therapy. Differently than brachytherapy,
177-Lutetium-PSMA is thought to have its effect not only to the cancer cells within the
prostate, but also to cancer cells located elsewhere in the body. Thus, the idea here is that
by adding 177Lutetium (Lu)- PSMA early in the course of treatment we may be able to
inactivate potential metastatic cells outside the prostate, while the prostate cancer within
this organ still treated by the combination of brachytherapy and 177-Lutetium-PSMA.